Calidi Biotherapeutics, Inc. (CLDI)

0.2320 -0.0070 (-2.93%) At close: 04:00PM EDT

Calidi Biotherapeutics, Inc.

4475 Executive Drive
Suite 200
San Diego, CA 92121
United States
858 794 9600
https://www.calidibio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 41

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Allan J. Camaisa	CEO & Chairman of the Board	306.18k	N/A	1961
Ms. Wendy Pizarro Campbell Esq.	Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer & Corporate Secretary	295.4k	N/A	1972
Dr. Boris Minev M.D., Ph.D.	President of Medical & Scientific Affairs and Interim Chief Medical Officer	400.1k	N/A	1964
Mr. Andrew C. Jackson	Chief Financial Officer	N/A	N/A	1969
Dr. Amish Patel Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	1977
Mr. Stephen Thesing	Chief Business Officer	N/A	N/A	1966

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Corporate governance

Calidi Biotherapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.